In vivo efficacy of top five surveyed Ghanaian herbal anti-malarial products by unknown
Wilmot et al. Malar J  (2017) 16:103 
DOI 10.1186/s12936-017-1757-4
RESEARCH
In vivo efficacy of top five surveyed 
Ghanaian herbal anti-malarial products
Dennis Wilmot1, Elvis Ofori Ameyaw1, Daniel Amoako‑Sakyi1, Johnson Nyarko Boampong1 
and Neils Ben Quashie2,3*
Abstract 
Background: Anti‑malarial herbal preparations (HPs) continue to enjoy high patronage in Ghana despite reports that 
the artemisinin‑based combination therapy (ACT), the recommended first choice for treatment of uncomplicated 
malaria in the country, remains efficacious. A major issue with the use of these preparations is inadequate or unreli‑
able data on their efficacy and quality. An assessment of the potency and quality of the most popular commercial 
anti‑malarial HPs in Ghana was, therefore, carried out. The outcome of this investigation is herein discussed preceded 
by a short literature review of herbal medicines in Ghana.
Methods: Using a questionnaire survey of 344 individuals in parts of Ghana, five of the most frequently used HPs 
were identified and selected for test of their efficacy and quality. The effect of the selected compounds on Plasmo-
dium berghei in vivo was assessed using standard methods.
Results: All five tested HPs (HP‑A, HP‑B, HP‑C, HP‑D and HP‑E) showed chemo‑suppressive activity against P. berghei 
in vivo. However the degree of parasites inhibition is significantly lower compared to the WHO‑recommended 
artemether–lumefantrine combination (p < 0.05, 99.9% chemosuppression/activity, 28 days survival). Using the Solo‑
mon Saker’s Test, two of the preparations were found to contain chloroquine or compounds with chemical properties 
like that of chloroquine.
Conclusion: Popular anti‑malarial HPs used in southern Ghana were found to have chemo‑suppressive properties. 
Intentional addition of chloroquine or SCs to these preparations in order to enhance their effectiveness has serious 
public health concerns as it may induce cross resistance to amodiaquine, one of the partner drugs in the recom‑
mended ACT for use in Ghana.
Keywords: Anti‑malarial drug, Plasmodium falciparum, ICR mice, Plasmodium berghei, Chemosuppression, Herbal‑
preparations, In vivo
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Background
The global fight against malaria is multi-faceted, employ-
ing a number of approaches including vector control and 
effective case management. The use of the ACT as first-
line treatment against uncomplicated malaria was rec-
ommended by the World Health Organization (WHO) 
in the mid-2000s and up to date, ACT has been used 
extensively in most disease endemic countries to manage 
the disease. In Ghana, artesunate–amodiaquine (AA) is 
the first choice, with artemether–lumefantrine (AL) and 
dihydroartemisinin-piperaquine (DHAP) as alternatives. 
The use of the ACT coupled with the implementation of 
other interventional measures has resulted in significant 
reduction in the incidence of malaria in Ghana lately. 
Despite this gain and reports that the ACT still remains 
efficacious in the country, commercial anti-malarial 
herbal preparations continue to enjoy high patronage in 
Ghana. This situation may be due to the fact that herbal 
medicine offers a cheaper alternative to allopathic medi-
cines. Worldwide, it is estimated that over 1200 plant 
species are used for the treatment of malaria and fevers, 
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and herbal preparations are potentially important sources 
of new anti-malarial treatments [1].
The practice of using herbal medicine to treat malaria 
in Ghana is indigenous and widespread. An ethno-botan-
ical survey of plants used by indigenous households in 
the Dangbe West District of Ghana revealed that a total 
of about 30 different species of plants are used by the 
people to treat malaria [2]. This trend could be similar 
in the other 215 districts in the country. Indeed, Bua-
beng et al.[3] demonstrated that about 9% of Ghanaians 
depend on HPs for the treatment of malaria. Of particu-
lar mention is Cryptolepis sanguinolenta, also known as 
nibima, which has been demonstrated to be clinically 
efficacious against malaria [4]. Herbal tea formulations 
of nibima, trademarked as Phyto-Laria, have been shown 
to offer 93.5% cure rate in vivo with no signs of toxicity. 
Other herbal formulation reported to have significant 
antiplasmodial activity for malaria treatment in Ghana 
include Tridax procumbens [5], Phyllanthus amarus [5], 
Theobroma cacao [6], Haematostaphis barteri [7] and 
Plumeria alba [8].
Plants showing anti-malarial activity need to be exam-
ined further in order to identify and unearth the potential 
phytochemicals present that may be responsible for the 
activity. Pursuing this will make herbal medicine a route 
for anti-malarial drugs discovery. In spite of the health 
benefit of herbal products, these preparations could also 
be a potential death trap. For instance, if the claimed cure 
by the peddler is not true, the life of the consumer may 
be at risk as high number of parasites may build up and 
may results in severe disease condition. Another health 
risk is when the preparation contains a toxic component. 
Again, if the HPs have active ingredients whose chemi-
cal properties are similar to certain allopathic drugs, then 
there could be cross resistance to such drugs as a conse-
quence of selection pressure. Adulteration of HPs with 
allopathic drugs in order to increase their potency has 
been reported [9]. Such practices could lead to parasites 
developing resistance to these allopathic drugs.
Whilst the Food and Drugs Authority (FDA) moni-
tors the toxicity of the commercially available HPs, the 
efficacy of most of these preparations remains unveri-
fied. With a public health approach, this study, therefore, 
explored the potency of some selected HPs in Ghana.
Methods
Survey sites
The survey was conducted in three Coastal regional capi-
tal cities shown in Fig.  1; Cape Coast (5° 6′ 0″ N/1° 15′ 
0″ W) in the Central Region; Takoradi (4° 53′ 0″ N/1° 45′ 
Fig. 1 Map of Southern Ghana showing the sites for the survey. Source Remote Sensing and Cartographic Unit, University of Cape Coast, 2013
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0″ W) in the Western Region; Accra (5° 33′ 0″ N/0° 13′ 
0″ W) in the Greater Accra Region of Ghana. These sites 
were selected based on population density.
Survey participants and sample size
This is an open gender-unbiased study. Individuals 
below the age of 18 years at the time of the questionnaire 
administration were excluded in the survey. Sampling at 
the street level was done randomly by interviewing every 
third individual or individuals from every second open 
shop. At the community level, every second house was 
chosen and the individuals in it were selected and inter-
viewed. Based on the 2010 population census in Ghana, 
the sample size was estimated using the formula pro-
posed by Cochran [10]. Three hundred and eighty-four 
(384) was the estimated sample size.
Selection of herbal preparations and source of drugs
The herbal preparations mentioned by respondents in 
the questionnaire survey as their choice for treatment 
of malaria are shown in Fig.  2. The five most patron-
ized HPs, as identified through the survey, were pur-
chased from licensed pharmacy shops in and around 
the selected study sites. The five HPs were designated 
as: HP-A, HP-B, HB-C, HB-D and HB-E. Chloroquine-
phosphate powder used as control in this study was a gift 
Fig. 2 List of identified HPs being used to treat malaria in the surveyed areas
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from Ernest Chemist. Artemether/lumefantrine (A–L), 
the designated standard allopathic anti-malarial drug was 
obtained from AJANTA Pharmaceutical Ltd (Mumbai, 
India).
Rodent parasite used for in vivo tests
Male ICR mice (25–30 g) were housed in the animal facil-
ity of the Department of Biomedical and Forensic Sciences, 
University of Cape Coast (UCC). The animals were housed 
in groups of five in stainless steel cages (34 × 47 × 18 cm) 
with soft wood shavings as bedding. They were fed with 
normal commercial pellet diet (AGRICCARE, Kumasi). 
Water was given ad libitum, under laboratory conditions. 
The cages were kept in an environment of constant tem-
perature (25–27  °C). All procedures and techniques used 
in these studies were in accordance with the National 
Institute of Health Guidelines for the Care and Use of Lab-
oratory Animals [11]. All protocols used were approved by 
the UCC Ethical Committee.
The rodent parasite (Plasmodium berghei NK65) used in 
this study was provided by the Noguchi Memorial Insti-
tute for Medical Research, University of Ghana, Legon, 
Ghana. The parasites were initially stored at −70 °C in the 
laboratories of the Department of Biomedical and Foren-
sic Sciences, University of Cape Coast until used.
Evaluation of the anti‑malarial activity of the HPs
The liquid HPs (1000  ml of each herbal product) were 
lyophilized with a freeze dryer. The anti-malarial effect 
of the selected HPs on P. berghei infection was evalu-
ated using the method described by Al-Adhroey et  al. 
[12]. Briefly, 85 male mice were each inoculated with 
1  ×  106 P. berghei on the first day. Seventy-two hours 
after parasite inoculation, different groups of mice (five 
mice per group), were treated with one of three differ-
ent doses, 10, 30 and 300 mg/kg p.o. of a chosen HP once 
per day. A group of five mice also received 4 mg/kg p.o. 
of artemether/lumefantrine (A–L). The negative control 
group, made up of also of five mice, was given 10 ml/kg 
p.o. normal saline. To determine the daily parasitaemia 
level, a drop of blood was collected from the tail of each 
mouse for preparation of thick and thin blood films on 
glass slide. The thin film was fixed with methanol and 
both films were stained with 10% Giemsa. The stained 
blood smears were then examined under the light micro-
scope at  100× magnification. Parasitaemia was esti-
mated as usual. The mean survival time of the mice in 
each treatment group was determined over a period of 
28 days.
Solomon Saker’s test for presence of chloroquine
The Solomon Saker’s test [13] was performed to ascer-
tain adulteration of the HPs with chloroquine or 
compounds with chemical components similar to chlo-
roquine. In brief, 1  ml nitrogen phosphate buffer and 
0.2  ml tetrabromophenyl phtaline solution were dis-
pensed into screw-cap conical centrifuge tubes. After 
addition of 2  ml HPs to the solution, the tubes were 
vigorously shaken for about 15  s and left to stand for 
about 15 min. The same was done for the positive con-
trol tubes which contain chloroquine at a concentra-
tions of 2 μg/ml (low concentration control) and 4 µg/
ml (high concentration control) respectively. A drug-
free tube containing distilled water instead of drug 
was used as negative control. A yellowish-green colour 
of the organic layer indicates a negative test for CQ 
and metabolites; a red to purple colour of the organic 
layer indicates a positive result with the shade of colour 
determined by the concentration of CQ and metabolites 
present.
Statistical analysis
GraphPad Prism for Windows version 4.03 (GraphPad 
Software, San Diego, CA, USA) was used for all statisti-
cal analyses. All data were expressed as mean  ±  SEM 
(duplicate measurement). The time-course curves were 
subjected to two-way (treatment × time) repeated meas-
ures analysis of variance (ANOVA) followed by Bonfer-
roni’s post hoc test. p < 0.05 was considered statistically 
significant.
Results
Outcome of the questionnaire survey
From the questionnaire survey, a total of 31 different 
herbal medicines were mentioned to have been used. The 
names of the herbal preparations mentioned as used by 
the respondents to treat malaria are shown in Fig. 2. Five 
most patronized herbal preparations, as revealed by the 
survey, were investigated in this study. For the purposes 
of anonymity, the HPs were designated HP-A, HP-B, 
HP-C, HP-D, and HP-E.
Effect of the herbal preparations on P. berghei infected 
mice
Of the five selected herbal products investigated, only 
HP-A showed a dosage-independent chemo-suppression 
of P. berghei. However, almost all the test compounds 
were observed to be able to reduce parasitaemia signifi-
cantly (p  <  0.05) and consistently throughout the entire 
test period (Fig.  3). Two-way ANOVA testing followed 
by Bonferroni’s post hoc test revealed a significance dif-
ference between parasitaemia observed for the HPs and 
negative control. Chemo-suppression of the parasites by 
A–L was seen to be over 1.15 times greater than that of 
HP-E which was found to have the highest chemo-sup-
pression activity.
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Chemo‑suppression of parasitaemia and mice survival 
period
The mice survival period and percentage chemo-sup-
pression of all the HPs as well as the control groups 
is shown in Figs.  4 and 5, respectively. Mice treated 
with HP-E survived up to day 28 of the test period. 
Mice given HP-A survived for the shortest number 
of days, 13  days, two less than those given Extracts B 
Fig. 3 Time course of parasitaemia in mice treated with HPs. It shows the daily percentage parasitaemia of all three concentrations of HPs (300, 100 
and 30 mg/kg body weight) compared to that of the negative control. Data is presented as mean ± SEM
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and C (15  days) and four less than those given HP-D 
(17 days).
Solomon‑Saker’s test for presence of chloroquine
In the Solomon Saker’s test, a light red colour was observed 
for the 2  μg/ml concentration of chloroquine and a red 
colour for the 4 μg/ml concentration of chloroquine. Two 
of the tested herbal preparations, HP-B and HP-C were 
found to exhibit colours similar to the positive control (high 
concentration, 4 μg/ml). This is indicative of the presence 
of high level of chloroquine or compounds with chemical 
properties similar to chloroquine in the two products.
Discussion
For various reasons, a number of Ghanaians prefer herbal 
medicine over the ACT for the treatment of malaria, 
although available evidence indicates that the latter are 
still potent against P. falciparum infections in Ghana. 
Whether these herbal medicines are able to provide the 
claimed cure or protection against the disease remains 
largely unknown. This study therefore ascertained the 
efficacies of five of the most popular herbal preparations 
in Ghana and the implication of the findings on malaria 
control in Ghana is herein discussed.
Medicinal plants have been used in the treatment and 
prevention of malaria in various parts of the world and if 
found to have excellent anti-malarial properties, a herbal 
preparation stands a chance of becoming a candidate for 
further development on a similar scale as that of the qui-
nine or artemisinin. The entire HPs investigated in this 
study exhibited chemo-suppression against P. berghei 
in  vivo. Notably, HP-E was able to protect the mice 
against the parasites for up to 28 day post-infection mak-
ing it worthy to receive attention for further future devel-
opment. None of the test HPs could completely bring 
down parasitaemia in the first 2  days post-treatment. 
This could probably be due to low bioavailability of the 
HP in the mice or insufficient dosage among others.
Since the HPs are chemo-suppressive, their inability 
to completely clear parasites should be of concern to the 
malaria control program as it poses a potential danger to 
the health of the users due to anticipated persistency or 
delayed parasite clearance. Another danger is the likeli-
hood of cross resistance if the HP shares similar chemi-
cal component with any of the recommended first line 
anti-malarial drugs, especially if the herbal medicine is 
not administered in the correct dosage. These observa-
tions made in this study are important as herbal medicine 
plays a significant role in the management of malaria in 
Ghana. Reports indicate that about 9% of the Ghanaian 
population use HPs for malaria treatment [3]. With the 
Fig. 4 Mice survival period, shows the number of days survived by 
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Fig. 5 Chemo‑suppression of parasitaemia, shows the percentage chemo‑suppression of parasitaemia for each treatment
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looming possibility of parasite resistance to the recom-
mended ACT [14] coupled with difficulties in afford-
ability and accessibility to these drugs in remote and 
poor areas in the country, anti-malarial herbal prepara-
tions would continue to be an important and sustainable 
source of malaria treatment in Ghana. It must however 
be emphasized that the use of these preparations must be 
closely monitored.
Solomon-Saker’s test indicated what could be the pres-
ence of chloroquine in the herbal preparation. This could 
be a case of intentional adulterations of the preparations 
in order to boost its efficacy. It is possible then, that chlo-
roquine or compounds with chemical properties similar to 
chloroquine was the active ingredient responsible for the 
chemo-suppression exhibited by HP-B and HP-C. How-
ever the Solomon-Saker’s test has been shown to give false 
positive results for the anti-malarial drugs, quinine and 
proguanil [13]. It is, therefore, possible that quinine con-
taining plants might have been used to prepare these two 
Solomon-Saker’s positive test compounds. Whatever the 
case may be the presence of chloroquine or compounds 
with chemical properties similar to chloroquine in these 
herbal preparations used by the Ghanaian public could 
foster the selection of chloroquine or quinine resistant 
clones in Ghana. For instance, Thompson et  al. showed 
that P. berghei developed resistance to quinine adminis-
tered in doses near the maximum amounts tolerated by 
mice [15]. This indicates the possibility of spontaneous or 
unintentional induction of parasite resistance to quinine 
or quinoline, by the use of an HP with similar chemical 
structure. The presence of these analogs in the HPs could 
probably explain the reasons for slow recovery of chloro-
quine sensitive clones in Ghana as reported by Afoakwah 
et al. [16]. Elsewhere, disuse of chloroquine resulted in the 
reversion of chloroquine sensitivity after a period [17].
Aside the possibility of adulterations with allopathic 
drugs or their analogs, the fact that these preparations 
were unable to completely clear parasites should be of 
public health concern as this could lead to the develop-
ment of severe form of the disease. It is however assur-
ing that the HPs showed some degree of anti-malarial 
activity. There is the need therefore to identify the active 
components in these HPs for further investigation and 
possible development to regulated drugs.
It must however be emphasized that since this study 
was performed using P. berghei in vivo, its comparison or 
extrapolation to field situation in Ghana, which is domi-
nated by P. falciparum infections, is limited by differ-
ences in both the rodent host and the strain of malaria 
parasite. Nonetheless, results of this study should stimu-
late further investigations of Ghanaian HPs using other 
methods, such as the in vitro susceptibility test of Plas-
modium falciparum to these preparations.
It is however interesting to note that in the course of 
preparation of this manuscript, Amoah et  al. published 
the outcome of a similar study conducted in Ghana which 
may likely include some of the HPs assessed in this study 
[18]. Though the approach was similar, their work rather 
focused on assessment among others, of the gametocidal 
effects of herbal malaria products in the country. Whilst 
this work was performed in vivo, theirs was done in vitro. 
They demonstrated that some of the preparations indeed 
have gametocidal effect but showed little action against 
the asexual stages. This is interesting, since HPs with 
high gametocidal activity can help in the fight to reduce 
malaria transmission.
Put together, both studies have demonstrated that most 
of the HPs in Ghana possess a significant anti-malar-
ial activity which justifies their use for the treatment of 
‘fever’. This should open the way for a systematic inter-
rogation of the chemical components of HPs present 
in Ghana in order to identify their active anti-malarial 
ingredients for isolation and further development.
Conclusion
All five tested HPs showed various degree of chemo-
suppressive activity against P. berghei in vivo. Two of the 
tested HPs have possibly been adulterated with chloro-
quine or compounds with chemical properties similar to 
chloroquine. Intentional adulteration of HPs with stand-
ard anti-malarial drugs should be of concern to stake 
holders in the health sector.
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